Selection of letters to be published is the decision of the editor. For acceptance, letters must be signed. A letter can appear anonymously if requested by the author. All letters are subject to editing. A letter that questions, criticizes, or responds to a previously published Clinical Journal of Oncology Nursing article automatically will be sent to the author of that article for a reply. This type of collegial exchange is encouraged. Send letters to CJONEditor@ons.org.
References
Zhao, Y., Ding, Y., Lu, Y., Zhang, J., Gu, J., & Li, M. (2013). Incidence and self-management of hand-foot syndrome in patients with colorectal cancer. Clinical Journal of Oncology Nursing, 17, 434-437. doi:10.1188/13.CJON.434-437
Cherici, C., Frazier, J. Feldman, M., Gordon, B., Petrykiw, C. A., Russell, W. L., & Souza, J. (2011).
Navigating drug shortages in American healthcare: A Premier healthcare alliance analysis. Retrieved from
http://www.premierinc.com/about/news/11-mar/drug-shortage-white-paper-3-28-11.pdf
Clapp, M., Rie, M. A., & Zweig, P. L. (2013, September 3). How a cabal keeps generics scarce. New York Times, p. A25.
Hospital group purchasing: Are the industry's reforms sufficient to ensure competition? Hearing before the Subcommittee on Antitrust, Competition Policy, and Consumer Rights, Senate, 109th Cong. 2 (2006).
Hospital group purchasing: Has the market become more open to competition? Hearing before the Subcommittee on Antitrust, Business Rights, and Competition of the Committee of the Judiciary, Senate, 108th Cong. 1 (2003).
Hospital group purchasing: How to maintain innovation and cost savings: Subcommittee on Antitrust, Competition Policy, and Consumer Rights, Senate, 108th Cong. 2 (2004).
Hospital group purchasing: Lowering costs at the expense of patient health and medical innovations?: Subcommittee on Antitrust, Business Rights, and Competition, Senate, 107th Cong. 2 (2002).
Litan, R. E., Singer, H. J., & Birkenbach, A. (2011). An empirical analysis of aftermarket transactions by hospitals. Journal of Contemporary Health Law and Policy, 28, 23-38.
McKeever, A. E., Rosen Bloch, J., & Bratic, A. (2013). Drug shortages and the burden of access to care: A critical issue affecting patients with cancer. Clinical Journal of Oncology Nursing, 17, 490-495. doi:10.1188/13.CJON.490-495
Moss, D. L. (2012).
Healthcare intermediaries: Competition and healthcare policy at loggerheads? Retrieved from
http://bit.ly/1hXZJVM
Porter, M. E., & Teisberg, E. O. (2006). Redefining healthcare: Creating value-based competition on results. Boston, MA: Harvard Business Review Press.
Sethi, S. P. (2009). Group purchasing organizations: An undisclosed scandal in the U. S. healthcare industry. New York, NY: Palgrave Macmillan.
U. S. Food and Drug Administration. (2013).
Strategic plan for preventing and mitigating drug shortages. Retrieved from
http://1.usa.gov/1mQ1QS0
U. S. Government Accountability Office. (2002).
Group purchasing organizations: Pilot study suggests large buying groups do not always offer hospitals lower prices. Retrieved from
http://www.gao.gov/assets/90/81813.pdf
U. S. Government Accountability Office. (2014).
Drug shortages: Public health threat continues, despite efforts to help ensure product availability. Retrieved from
http://www.gao.gov/assets/670/660785.pdf
Woodcock, J., & Wosinska, M. (2013). Economic and technological drivers of generic sterile injectable drug shortages. Clinical Pharmacology and Therapeutics, 93, 170-176.